Aim: To assess the risk of hypoglycaemia (TBR) in persons with diabetes who are on SUs with fairly controlled diabetes (HbA1c between 7 to 8%) .
Background: Sulphonylurea (SU) is conventionally used as a powerful glucose lowering agent and is known to increase the risk of hypoglycaemia. This paper is an attempt to study the effect of SUs on persons with diabetes by introducing continous glucose monitoring (CGM/AGP) which can help clinicians optimise diabetes treatment along with nutrition which can reduce the risk of hypoglycaemia.
Methodology: A retrospective analysis was done at our diabetes care centre. A total of 300 persons with type 2 diabetes on AGP and on SU therapy were studied. Only those persons with HbA1c between 7 to 8%, indicating fairly controlled diabetes were included.
Results: It was observed that no hypoglycaemia was present in 74% of the persons under study as per AGP data. Only 26% had hypoglycaemia grade 1 with less than 5% TBR; 2% had hypoglycaemia in TBR more than 5%, out of which only one person reported symptoms of severe hypoglycaemia. One of the AGP data of person with diabetes is attached in the image.
Conclusion: Judicious use of sulphonylureas does not increase risk of hypoglycaemia (Time Below Range) in type 2 diabetics as traditionally believed.
T.C.Vyas: None. B.D.Saboo: None. K.Chennamsetti: None. J.Kesavadev: None. B.Saboo: None. D.Hasnani: None. V.Chavda: None. D.Panchal: None.